MARKET

ALDX

ALDX

Aldeyra
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.420
-0.090
-2.56%
Closed 17:13 01/26 EST
OPEN
3.550
PREV CLOSE
3.510
HIGH
3.720
LOW
3.380
VOLUME
1.10M
TURNOVER
--
52 WEEK HIGH
15.95
52 WEEK LOW
3.000
MARKET CAP
198.67M
P/E (TTM)
-3.1469
1D
5D
1M
3M
1Y
5Y
HealthInvest Partners AB Buys McKesson Corp, Cardinal Health Inc, AmerisourceBergen Corp, Sells ...
Stockholm, V7, based Investment company HealthInvest Partners AB (Current Portfolio) buys McKesson Corp, Cardinal Health Inc, AmerisourceBergen Corp, Bristol-Myers Squibb Co, AbbVie Inc, sells Supernus Pharmaceuticals Inc, Accuray Inc, Aldeyra Therapeutics...
GuruFocus.com · 01/18 18:38
BRIEF-Aldeyra Therapeutics Announces Positive Top-Line Data From Phase 2 Dry Eye Chamber Clinical Trial Of Reproxalap, An Investigational New Drug, Compared To Xiidra
reuters.com · 01/11 14:05
Aldeyra reports positive top-line data from Phase 2 reproxalap study in dry eye disease
Aldeyra Therapeutics (NASDAQ:ALDX) announces positive top-line data from a Phase 2 clinical trial comparing ocular discomfort and itching symptom scores of reproxalap ophthalmic solution 0.25% (reproxalap), versus Xiidra (lifitegrast ophthalmic
Seekingalpha · 01/11 13:38
Aldeyra Therapeutics Announces Top-Line Data From Phase 2 Dry Eye Chamber Clinical Trial Of Reproxalap; Says Reproxalap Patient-Reported Ocular Discomfort And Itching Were Statistically Lower Than With Xiidra
Reproxalap Statistically Lower than Xiidrafor the Two Endpoints of the Trial: Ocular Discomfort (p=0.002) and Ocular Itching (p=0.01) Results Consistent with Data from Post-Acute Ocular Tolerability Comparison of
Benzinga · 01/11 13:05
Aldeyra Therapeutics Announces Positive Top-Line Data from Phase 2 Dry Eye Chamber Clinical Trial of Reproxalap, an Investigational New Drug, Compared to Xiidra®
LEXINGTON, Mass., January 11, 2022--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company discovering and developing innovative therapies for the treatment of immune-mediated diseases, today announced positive top-line data from a Ph...
Business Wire · 01/11 13:00
Woodstock Corp Buys Amgen Inc, Applied Materials Inc, FedEx Corp, Sells Reata Pharmaceuticals ...
Boston, MA, based Investment company Woodstock Corp (Current Portfolio) buys Amgen Inc, Applied Materials Inc, FedEx Corp, Southwestern Energy Co, Sun Life Financial Inc, sells Reata Pharmaceuticals Inc, Aldeyra Therapeutics Inc, Epizyme Inc, International...
GuruFocus.com · 01/07 18:38
Aldeyra Therapeutics completes enrollment in part 1 of phase 3 study of eye disorder drug
Aldeyra Therapeutics (ALDX -0.6%) completed enrollment in part 1 of phase 3 GUARD trial of ADX-2191 (intravitreal methotrexate 0.8%) in patients with a type of rare eye disorder called proliferative vitreoretinopathy (PVR).
Seekingalpha · 01/04 16:50
BRIEF-Aldeyra Therapeutics Completes Enrollment In Part 1 Of Phase 3 Guard Trial Of ADX-2191
reuters.com · 01/04 14:41
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ALDX. Analyze the recent business situations of Aldeyra through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

50.00%Strong Buy
50.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ALDX stock price target is 20.40 with a high estimate of 30.00 and a low estimate of 10.00.
High30.00
Average20.40
Low10.00
Current 3.420
EPS
Actual
Estimate
-0.24-0.18-0.12-0.06
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 152
Institutional Holdings: 42.65M
% Owned: 73.41%
Shares Outstanding: 58.09M
TypeInstitutionsShares
Increased
28
1.91M
New
16
1.25M
Decreased
44
3.48M
Sold Out
33
4.80M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.73%
Pharmaceuticals & Medical Research
-0.45%
Key Executives
Non-Executive Chairman/Independent Director
Richard Douglas
President/Chief Executive Officer/Director
Todd Brady
Chief Financial Officer
Joshua Reed
Other
Stephen Machatha
Independent Director
Ben Bronstein
Independent Director
Martin Joyce
Independent Director
Nancy Miller-rich
Independent Director
Gary Phillips
Independent Director
Neal Walker
No Data
About ALDX
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in developing immune-modulating therapies to treat ocular and systemic diseases. The Company's lead product candidate, reproxalap, is a treatment in late-stage development for dry eye disease (DED) and allergic conjunctivitis (AC). It has additional product candidates in development for proliferative vitreoretinopathy (PVR), primary vitreoretinal lymphoma (PVRL) and other retinal diseases, autoimmune disease, and cancer. The Company's product development pipeline is focused on immune-mediated ocular diseases and select systemic diseases and encompasses three biological mechanisms of action: reactive aldehyde species (RASP) inhibition, dihydrofolate reductase (DHFR) inhibition, and protein chaperome (CHP) inhibition. The immunological activity of its product candidates generally leads to diminished levels of pathological inflammation via down-regulation of immune cell activation or proliferation.

Webull offers kinds of Aldeyra Therapeutics Inc stock information, including NASDAQ:ALDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALDX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALDX stock methods without spending real money on the virtual paper trading platform.